Management of Hypocalcemia in Infants

Acute Assessment & Intravenous Therapy

Symptomatic hypocalcemia (e.g., seizures, tetany, laryngospasm) warrants immediate intravenous calcium administration regardless of the measured calcium level. 2
After an initial bolus, a continuous infusion of calcium gluconate at 0.5–1.5 mg/kg/h over 8–10 hours should be started if symptoms persist or calcium remains critically low. 2
Calcium gluconate is preferred over calcium chloride because it carries a lower risk of tissue necrosis if extravasation occurs. 3
Use a secure, large‑bore intravenous line and infuse calcium slowly (minimum 10 minutes) to avoid cardiac arrest. 3
Continuous cardiac monitoring is mandatory throughout all intravenous calcium administration. 3

Obtain a serum magnesium level immediately; hypomagnesemia is the most common cause of refractory hypocalcemia in infants and must be corrected before escalating calcium therapy. 4
Measure parathyroid hormone (PTH), phosphorus, 25‑hydroxyvitamin D, and creatinine to differentiate hypoparathyroidism from vitamin D deficiency or other etiologies. 2
Low or inappropriately normal PTH + hyperphosphatemia suggests hypoparathyroidism (genetic, autoimmune, or syndromic). 4
Elevated PTH + low/normal phosphate indicates secondary hyperparathyroidism due to vitamin D deficiency. 4
Serum magnesium < 1.5 mg/dL requires magnesium supplementation before further calcium therapy because low magnesium impairs PTH secretion and action. 4

Prescribe liquid calcitriol 0.02–0.1 µg/kg/day, divided three times daily. 5
Prescribe calcium carbonate 40–60 mg/kg/day (elemental calcium), divided three times daily and given with meals to improve absorption. 5
Target a low‑normal to mid‑normal serum calcium range (avoid high‑normal levels) to minimize the risk of hypercalciuria and nephrocalcinosis. 5
Maintain serum phosphorus, magnesium, and 25‑hydroxyvitamin D within their respective normal reference ranges. 5

Initial stabilization: Re‑measure albumin‑corrected calcium 4–7 days after any dose adjustment. 5
During acute management or dose titration, monitor serum calcium weekly to monthly depending on stability. 2
Long‑term surveillance: Once stable, check serum calcium, phosphorus, magnesium, and 25‑hydroxyvitamin D every 3–12 months. 4
Perform a spot urine calcium‑to‑creatinine ratio (or 24‑hour urine calcium) every 6–24 months to detect hypercalciuria. 5
Obtain a renal ultrasound annually to screen for nephrocalcinosis or nephrolithiasis. 5

If 25‑hydroxyvitamin D is < 30 ng/mL, initiate cholecalciferol or ergocalciferol repletion rather than calcium alone. 6
Provide magnesium supplementation (oral magnesium oxide or intravenous magnesium sulfate) until serum magnesium exceeds 1.5 mg/dL. 4
When genetic hypoparathyroidism is suspected, arrange genetic counseling and germline mutation testing. 2
Recognize that activating mutations of the calcium‑sensing receptor (CaSR) cause autosomal‑dominant hypocalcemia with inappropriately normal PTH. 4

Do not start calcium therapy without first checking magnesium, as uncorrected hypomagnesemia renders calcium repletion ineffective. 4
Avoid targeting high‑normal calcium levels, which increase the calcium‑phosphate product and promote ectopic calcifications in the brain, kidneys, and vasculature. 2
Do not rely solely on total calcium in hypo‑albuminemic infants; measure ionized calcium to avoid missing true hypocalcemia. 6
Be aware that calcitriol raises both serum phosphorus and urinary calcium; monitor for hypercalciuria when using active vitamin D. 4
Never administer IV calcium rapidly; infuse over at least 10 minutes to prevent cardiac arrest. 3